Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer

  • Johann de Bono | johann.de-bono@icr.ac.uk Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom.
  • Liji Shen Sanofi, Bridgewater, NJ, United States.
  • Oliver Sartor Tulane University Medical School, New Orleans, LA, United States.

Abstract

Not available.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2016-03-31
Info
Issue
Section
Letters to the Editor
Supporting Agencies
The TROPIC study was sponsored by Sanofi. Editorial support in the preparation of this letter was provided by Danielle Lindley of MediTech Media funded by Sanofi.
Keywords:
TROPIC, Cabazitaxel, Mitoxantrone
Statistics
  • Abstract views: 2074

  • PDF: 904
How to Cite
de Bono, J., Shen, L., & Sartor, O. (2016). Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer. Archivio Italiano Di Urologia E Andrologia, 88(1), 72-73. https://doi.org/10.4081/aiua.2016.1.72